The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?

Characterizing drug substance properties early can optimize drug product formulation

Whitepaper

Changes in the Drug Substance (DS) process as it scales up can affect the Drug Product (DP). As processes change, many properties of the DS can also change. Therefore, as DS manufacturers evaluate and optimize the synthetic route, process conditions, crystallization solvents, etc., they must understand and track these changes, and discuss them with DP formulators to anticipate challenges in formulation.

Learn how collaboration between DS chemists and DP formulators on a formulation development strategy can save time, money, and avoid rework.

Author: Anil Kane, PhD, MBA, Global Head of Technical and Scientific Affairs, Formulation, Patheon